Associated Papers
Genetic variants of cytochrome P450 2C21 identified by screening 6344 dogs influenced oxidations of the probe drug omeprazole.
Uno Y et al.
Biochemical Pharmacology, 2025
Frequencies of CYP2C9 polymorphisms in a Syrian cohort.
Aldiban W et al.
Bmc Genomics, 2025
Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan.
Parikh SJ et al.
Journal of Inorganic Biochemistry, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
A call for increased inclusivity and global representation in pharmacogenetic testing.
Kennedy A et al.
Npj Genomic Medicine, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen.
Yuan LJ et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
Giraldo-Ocampo S et al.
Medicine, 2023
Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences.
Zhou Y et al.
Human Genomics, 2023
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E et al.
Plos One, 2022
Genetic Analysis of CYP2C9 with Reference to Drug Response in Epilepsy Patients of Pakistan.
Maqbool H et al.
Genetics Research, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Pharmacogenetic determinants of warfarin in the Indian population.
Naushad SM et al.
Pharmacological Reports : Pr, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations.
Nizamuddin S et al.
Pharmacogenomics and Personalized Medicine, 2021
An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62.
Chen H et al.
Chemico-biological Interactions, 2020
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
El Rouby N et al.
Clinical and Translational Science, 2020
Functional Characterization of Pharmcogenetic Variants of Human Cytochrome P450 2C9 in Korean Populations.
Cho MA et al.
Biomolecules & Therapeutics, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
Langaee T et al.
Genetic Testing and Molecular Biomarkers, 2019
Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population.
Ahmed S et al.
Genes, 2018
The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro.
Xu RA et al.
Infection and Drug Resistance, 2018
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
Arwood MJ et al.
Clinical Pharmacology and Therapeutics, 2017
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.
Shirasaka Y et al.
The Pharmacogenomics Journal, 2016
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biological & Pharmaceutical Bulletin, 2016
In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population.
Dai DP et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2015
Warfarin dose requirements in a patient with the CYP2C9*14 allele.
Lee YM et al.
Pharmacogenomics, 2014
Functional characterization of 32 CYP2C9 allelic variants.
Niinuma Y et al.
The Pharmacogenomics Journal, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient.
Ciccacci C et al.
Pharmacogenetics and Genomics, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2010
A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.
Lee SJ et al.
British Journal of Clinical Pharmacology, 2010
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan.
Yin T et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension, 2008
Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.
D'Andrea G et al.
Blood Reviews, 2008
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T et al.
Thrombosis Research, 2007
Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.
Maekawa K et al.
Pharmacogenetics and Genomics, 2006
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.
Daly AK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006